ICIs has been an increasing rising up clinical method and holds great promise for treating ccRCC [9], but the effective biomarkers for predicting immune response are still lacking, the well accepted immune prediction biomarkers in other cancers for instance PD-L1 expression, MSI status and TMB haven’t been supported thoroughly by evidence-based medicine to be effective in ccRCC [45, 46]. This evidence concerns the gene CD274 and cancer.